Corporate Information

In the field of pharmaceuticals, Wockhardt is gaining a reputation in several parts of the world as a name to trust. Over the past 45 years, starting from its roots in India, Wockhardt has grown to a billion dollar worldwide organization, today spanning 14 countries in 5 continents. More than 7,900 employees working in offices, 14 manufacturing facilities, 5 research centers, and hospitals are completely dedicated to building an important trust in our products.

We believe that quality medicines begin with strong science and that the quality of our products is directly related to the integrity of our people. Over 525 Quality Control and Quality Assurance scientists guarantee that Wockhardt's products and its 14 worldwide manufacturing facilities and 5 research centers meet the strict quality standards set by the FDA. Our world-class global R&D facilities are at the heart of Wockhardt's pledge and commitment to deliver high quality medicines at affordable prices and all are fully compliant with cGMP quality standards.

Please visit our corporate website at for more information.

Management Team

"An experienced leadership team of industry professionals committed to serving the US healthcare marketplace with high-quality products and innovative treatment solutions and education."

USA History

"Wockhardt has a strong track record of acquisition management, forming strategic alliances and developing a world-class organization and culture."

Wockhardt Limited created its US subsidiary Wockhardt USA in early 2004 with a modest portfolio of three FDA–approved generic products.  Since inception, Wockhardt’s business has increased in the US. Today, Wockhardt USA LLC is leading the way in developing the most complete, high-quality line of generic oral solids, liquids, topicals, and injectables available in the United States. Wockhardt USA now represents more than 41% of Wockhardt Ltd's global business, providing more than 257 NDCs spanning more than 66 different product families. We have been producing and distributing quality products in the United States for more than 8 years and have received over 110 ANDA approvals to date.

Chicago-based Morton Grove Pharmaceuticals was acquired by Wockhardt Limited in October 2007 in order to expand Wockhardt’s product line in the US. Since 1995, Morton Grove has been a leading manufacturer and marketer of oral liquid and topical pharmaceuticals. The company’s core products are manufactured in its 125,000 square foot, state-of-the-art facility.

To see USA highlights, click here.

  2013, Wockhardt USA, All Rights Reserved
Legal Disclaimer    |    Terms of Use    |    Privacy Policy